DA
REGN icon

Denali Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Denali Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Buy
1,000
+500
+100% +$340K 0.06% 236
2026
Q1 		$386K Buy
500
+100
+25% +$76.6K 0.04% 258
2025
Q4 		$309K Buy
+400
New +$272K 0.03% 286
2021
Q3 		– Sell
-100
Closed -$56K – 314
2021
Q2 		$56K Hold
100
– – 0.02% 175
2021
Q1 		$47K Buy
+100
New +$48.7K 0.01% 227
2020
Q3 		– Sell
-100
Closed -$62K – 397
2020
Q2 		$62K Buy
+100
New +$56.8K 0.01% 317

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Denali Advisors's REGN Position: Q2 2026 in Review

Denali Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 100% in Q2 2026, buying an estimated $340K and bringing the position to 1,000 shares worth $624K. The position accounts for 0.06% of the portfolio, ranked #236.

Denali Advisors first reported a position in REGN in Q2 2020 and has held it in 6 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Denali Advisors held 1,000 shares of Regeneron Pharmaceuticals worth $624K as of Q2 2026.
  • Denali Advisors bought 500 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $340K.
  • Regeneron Pharmaceuticals made up 0.06% of Denali Advisors's portfolio in Q2 2026, its #236 holding.
  • Denali Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 6 quarters since.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Denali Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.